GlobeNewswire: Aequus Pharmaceuticals Contains the last 10 of 166 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T11:49:59ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/08/30/2733996/0/en/Aequus-Reports-Second-Quarter-2023-Financial-Highlights-and-General-Update.html?f=22&fvtc=4&fvtv=45517Aequus Reports Second Quarter 2023 Financial Highlights and General Update2023-08-30T01:53:33Z<![CDATA[VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, today reports financial results for the quarter ended June 30, 2023 (“Second Quarter 2023”) and associated Company developments. Unless otherwise noted, all figures are in Canadian currency.]]>https://www.globenewswire.com/news-release/2023/08/24/2731083/0/en/Aequus-Announces-Zimed-PF-Now-Available-in-Canada.html?f=22&fvtc=4&fvtv=45517Aequus Announces Zimed PF Now Available in Canada2023-08-24T12:00:00Z<![CDATA[VANCOUVER, British Columbia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), ) (“Aequus” or the “Company”), a specialty pharmaceutical company announced today, we are thrilled to announce the launch of Zimed® PF, the first preservative-free multi-dose Bimatoprost for glaucoma patients in Canada.]]>https://www.globenewswire.com/news-release/2023/08/22/2729420/0/en/Aequus-Announces-Zimed-PF-Website-Launch.html?f=22&fvtc=4&fvtv=45517Aequus Announces Zimed PF Website Launch2023-08-22T12:00:00Z<![CDATA[VANCOUVER, British Columbia, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), ) (“Aequus” or the “Company”), a specialty pharmaceutical company, are thrilled to announce the launch of our user friendly education website for patients and professionals. With a focus on elevated, interocular pressure, Glaucoma and Dry Eye Disease, this website features Zimed® PF, the first preservative-free multi-dose Bimatoprost available in Canada. The response from Canadian physicians at the 2023 annual COS conference in Quebec City has been nothing short of exceptional.]]>https://www.globenewswire.com/news-release/2023/08/18/2727919/0/en/Aequus-Pharmaceutical-Canada-Announces-a-Pause-in-Sales-of-Evolve-Intensive-Eyedrops-and-Gel-in-Canada.html?f=22&fvtc=4&fvtv=45517Aequus Pharmaceutical Canada Announces a Pause in Sales of Evolve Intensive Eyedrops and Gel in Canada2023-08-18T12:00:00Z<![CDATA[VANCOUVER, British Columbia, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), ) (“Aequus” or the “Company”), a specialty pharmaceutical company announces the pause of sales of its Evolve Intensive eyedrop and Intensive gel products in Canada.]]>https://www.globenewswire.com/news-release/2023/07/06/2700882/0/en/Aequus-Announces-Financing-to-Support-Launch-of-Zimed-Preservative-Free-Bimatoprost-0-03.html?f=22&fvtc=4&fvtv=45517Aequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%)2023-07-06T23:21:51Z<![CDATA[VANCOUVER, British Columbia, July 06, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announces today it has increased its debt by $400,000 to support the launch of Zimed® PF. Mr. Doug Janzen, Chairman and Chief Executive Officer of the Company, has agreed to provide financing to Aequus by way of an unsecured demand loan of C$400,000 (the “Loan”). The Loan bears interest at an annual rate of two and a half percent (2.5%) to be calculated and repaid monthly and is repayable on demand. “We remain very excited about the commercial prospects for Zimed and these funds will be used to support operations as we work to a successful launch in August,” said Mr. Janzen.]]>https://www.globenewswire.com/news-release/2023/05/31/2678940/0/en/Aequus-Provides-General-Update-and-First-Quarter-2023-Financial-Highlights.html?f=22&fvtc=4&fvtv=45517Aequus Provides General Update and First Quarter 2023 Financial Highlights2023-05-31T00:23:14Z<![CDATA[VANCOUVER, British Columbia, May 30, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the quarter ended March 31, 2023 (“First Quarter 2023”) and associated Company developments. Unless otherwise noted, all figures are in Canadian currency.]]>https://www.globenewswire.com/news-release/2023/05/02/2658715/0/en/Aequus-Provides-General-Update-and-Fiscal-2022-Financial-Results.html?f=22&fvtc=4&fvtv=45517Aequus Provides General Update and Fiscal 2022 Financial Results2023-05-02T01:12:36Z<![CDATA[VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company focused on bringing healthcare solutions to Canadians through licensing and partnerships, today reports financial results for the year ended December 31, 2022 (“Fiscal 2022”) and associated Company developments. Unless otherwise noted, all figures are in Canadian currency.]]>https://www.globenewswire.com/news-release/2023/04/19/2650521/0/en/Aequus-Grants-Stock-Options.html?f=22&fvtc=4&fvtv=45517Aequus Grants Stock Options2023-04-19T20:05:00Z<![CDATA[VANCOUVER, British Columbia, April 19, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announces that it has granted incentive stock options (the “Options”) to certain directors, officers, employees, and consultants of the Company to purchase up to an aggregate of 2,775,000 common shares of the Company. These stock options are exercisable at a price of $0.03 per share, for a term of eight years, and vest in tranches over a 3 year period. The options are subject to the terms and conditions of the Company’s stock option plan and the policies of the TSX Venture Exchange.]]>https://www.globenewswire.com/news-release/2023/04/05/2641684/0/en/Aequus-Announces-Financing-to-Support-Launch-of-Zimed-Preservative-Free-Bimatoprost-0-03-and-Board-Update.html?f=22&fvtc=4&fvtv=45517Aequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%) and Board Update2023-04-05T12:30:00Z<![CDATA[VANCOUVER, British Columbia, April 05, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), announced today it has entered into a loan agreement to raise $500,000 to support the launch of Zimed® PF. Mr. Doug Janzen, Chairman and Chief Executive Officer of the Company, will provide financing to Aequus by way of an unsecured demand loan of C$500,000 (the “Loan”). The Loan bears interest at an annual rate of two and a half percent (2.5%) to be calculated and repaid monthly and is repayable on demand. “We are very excited about the commercial prospects for Zimed and these funds are earmarked for launch and pre-launch activities,” said Mr. Janzen.]]>https://www.globenewswire.com/news-release/2022/12/20/2577073/0/en/Aequus-Announces-Health-Canada-Notice-of-Compliance-NOC-for-Zimed-Preservative-Free-Bimatoprost-0-03.html?f=22&fvtc=4&fvtv=45517Aequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%) 2022-12-20T13:30:00Z<![CDATA[VANCOUVER, British Columbia, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), is pleased to announce that Health Canada has approved Zimed® PF (Bimatoprost 0.03%) for the reduction of elevated intraocular pressure (IOP) in patients with open-angled glaucoma or ocular hypertension. Affecting more than 700,000 people in Canada, glaucoma is one of the leading causes of blindness in North America.]]>